Tag: SWING BTK

6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe

Sundance™ Sirolimus DCB demonstrates lowest binary restenosis at 6 months compared to relevant BTK clinical trials Excellent safety profile observed with no major amputations and low rates of MAE EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, […]